The p 21 activated kinase-1 (Pak1) is a serine-threonine protein kinase directly activated by Cdc42 and Rac1. In cardiac myocytes, Pak1 activation leads to dephosphorylation of cTnI and C-protein through upregulation of phosphatase-2A (PP2A). Pak1 activity is directly correlated with its autophosphorylation, which occurs upon binding to the small GTPases and to some small organic molecules as well. In this report, we describe a novel method for rapid purifi cation of endogenous Pak1 from bovine ventricle muscle. The method is simple and easy to carry out. The purifi ed Pak1 demonstrated autophosphorylation in vitro that was enhanced by D-erythro-sphingosine-1, N-acetyl-D-erythro-sphingosine (C 2 -ceramide), and N-hexanoyl-D-erythro-sphingosine (C 6 -ceramide). Dihydro-L-threo-sphingosine (saphingol) also had some effect on Pak1 autophosphorylation. The method we developed provides a useful tool to study Pak1 activity and regulation in the heart. Moreover, our results indicate a potential role of the sphingolipids as unique signaling molecules inducing a direct activation of Pak1 that may modulate different cardiac functions.
Despite strong evidence indicating an important role of p 21 activated kinase (Pak) in various tissues, detailed understanding of its signaling mechanisms remains poorly understood (Zhao and Manser 2005 ). An important step in identifying these mechanisms is the development of methods for purifi cation of the enzyme. We describe here a novel approach that we developed for isolation of Pak1 from ventricular myocardium, which will also be useful in other tissues.
Pak1 belongs to a family of serine/threonine protein kinases directly activated by small GTPases, Cdc42 and Rac1. In the heart, Pak1 is abundant and localizes to cell and nuclear membranes, intercalated discs and to Z-discs in ventricular myocytes. The active form of Pak1 in cardiomyocytes increases Ca 2+ sensitivity of myofi lament force development through activation of PP2A (Ke et al 2004) and in SA nodal cells, Pak1 inhibits isoproterenol stimulated activation of L-type Ca 2+ channel and delayed rectifi er potassium channels (Ke et al 2007a) . Other studies have shown that in endothelial cells, Pak1 activation induces dephosphorylation of myosin regulatory light chain and inhibition of thrombin-induced barrier dysfunction (Ke et al 2007b) and in HeLa cells, expression of constitutively active Pak1 induces loss of stress fi bers and dissolution of focal adhesion complexes (Manser et al 1997) . These studies suggest a role of Pak1 in cytoskeletal function and reorganization. In transgenic mice expressing an active Rac1 in the heart, hypertrophy developed followed by dilated cardiomyopathy with altered intracellular partitioning of Pak1 in the ventricle myocytes (Sussman et al 2000) .
A prominent post-translational modifi cation of Pak1 is autophosphorylation, which is correlated with its activity (Manser et al 1997; Zhao et al 1998) . Pak1 is autophosphorylated at seven serine/threonine sites most of which occur at the N-terminal half of the kinase. Substitution of threonine 423, the last autophosphorylation site, with glutamic acid renders the kinase constitutively active (Manser et al 1997) .
Although there is abundant expression of Pak1 in cardiomyocytes, smooth muscle and endothelial cells, the function of Pak1 in the cardiovascular system remains poorly understood (Sheehan et al 2007) . Moreover, potential modifi cations in autophosphorylation of native Pak1 in failing heart and in other pathological conditions have not been defi ned.
Studies in skeletal muscle have shown that Pak1 activity was responsive to insulin treatment (Tsakiridis et al 1996) suggesting that Paks are also phosphorylated by tyrosine kinase (Bagheri-Yarmand et al 2001; He et al 2004; Yang et al 2004) . Tyrosine phosphorylation of Pak1 may also play an important role in regulation of cardiac function. However, little is known about any tyrosine kinase signaling mechanism that may play a role in Pak activity.
In order to further study Pak1 function in the heart, we developed a novel affi nity chromatography method to purify endogenous Pak1 from heart muscle homogenate. A synthetic peptide derived from Pak1 protein with an HA tag that binds to HA matrix specifi cally retains Pak1 in the matrix and thus enriches Pak1 from tissue homogenate. A clear, single Pak1 protein band was detected from the eluant. The purifi ed Pak1 demonstrated autophosphorylation that was stimulated by sphingosine and sphingosine derivatives.
Methods

Preparation of muscle sample
Frozen bovine ventricle muscle (200 g) was cut into small pieces and homogenized in a blender containing 1 liter homogenization buffer (50 mM Tris base, 5 mM EDTA, 2 mM EGTA, 1 mM DTT, 0.5 mM benzamidine, 0.1 mM PMSF, pH 7.2). The homogenized muscle sample was centrifuged at 4500 g for 30 minutes. The supernatant fraction was saved and precipitated with ammonium sulfate (NH 4 ) 2 SO 4 at concentration 25% and 50% (w/v). Precipitates formed by (NH 4 ) 2 SO 4 addition between concentration 25% (w/v) and 50% (w/v) were saved and dialyzed against the homogenization buffer. After dialysis, the sample was fi ltered and lyophilized. For purifi cation of Pak1 from smaller amounts of sample, the tissues or cells were homogenized in mammalian extraction buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 0.1% Nonide P40; Complete Protease inhibitor cocktail tablets [Roche Diagnostics, cat # 11 873 580 001]). The ratio of tissue:buffer was about 1:5 (v/v). The homogenate was centrifuged in a bench-top centrifuge at 4 °C. The supernatant fraction was saved for direct application onto the affi nity column.
Peptide synthesis and the matrix
The peptides were synthesized in the University of Illinois at Chicago protein core facility. The decoy peptide (YNSKKTSNSQKYMSFTDKSAYPYDVPDYA) contained the Pak1 sequence from amino acids 131 to 150 linked to a 9 amino acid of infl uenza hemagglutinin (HA) epitope. The peptide derived from the N-terminal region of Pak1 with the sequence MSNNGLDIQDKPPAPPMRNTSTYPYDVPDYA was also used in some purifi cation. The Anti-HA Affi nity Matrix (Cat. No. 1 815 016) was purchased from Roche Applied Science (Indianapolis, IN, USA). The affinity matrix contains antibody specifi cally bind to HA sequence in protein or peptide.
Affi nity chromatography
The column was fi rst washed with 20 ml equilibration buffer (20 mM Tris, pH 7.5; 0.1 M NaCl; 0.1 mM EDTA). Decoy peptide (3 mg) was applied to the column to saturate the matrix with the peptide. The muscle sample (the lyophilized extract) was dissolved in buffer (20 mM Tris, pH 7.5; 0.1 M NaCl; 0.1 mM EDTA) containing protease inhibitor cocktail tablets. The sample was loaded onto the affi nity column and then washed with 20 ml washing buffer (20 mM Tris, pH 7.5; 0.1 M NaCl; 0.1 mM EDTA; 0.05% Tween-20). The Pak1 bound to the gel was eluted with equilibration buffer containing HA peptide (YPYDVPDYA) at 1 mg/ml. HA peptide was removed from the sample by dialysis in buffer containing 20 mM HEPES, 5 mM NaCl, pH 7.2. The bound Pak1 could also be eluted with 5 ml glycine buffer, pH 2.5 (50 mM glycine-HCl; 0.1 % Triton X-100; 0.15 M NaCl).
Kinase assay
Pak1 kinase activity was assayed in the following reaction buffer: 50 mM HEPES, pH 7.3, 10 mM MgCl 2 , 1 mM DTT, 0.05% Triton X-100) with 10 μCi of [γ 32 P] ATP (Perkin Elma. [γ-
32 P]-Adenosine 5`-triphosphate, Specifi c Activity: 3000Ci (111TBq)/mmole, 50 mM Tricine (pH 7.6), Concentration: 5 mCi/mL, Catal NEG502H250UC) at 37 °C for 2 h. The kinase reaction was stopped by adding SDS sample buffer followed by boiling for 5 min. Agonists added to the buffer were as described in the Results section and the fi gure legends. Agonists from Calbiochem included the following: C 2 ceramide (N-acetyl-D-erythro-sphingosine), C 6 ceramide (N-Hexanoyl-D-erythro-sphingosine) and safi ngol (Dihydro-L-threo-sphingosine). D-sphingosine (S 6879), and sphingosine 1-phosphate (S 9666) were purchased from Sigma (St. Louis, MO, USA). Sphingosines were dissolved in dimethyl sulfoxide. The total reaction volume was 20 μl. Dimethyl sulfoxide (2 μl) was included in each reaction including the control. Figure 1 show results of immuno-histochemical studies in rat ventricular myocytes demonstrating high and localized expression of Pak1. The bleb in the image of Figure 1A (upper panel) indicates sarcolemmal localization. Pak 1 also localized to the nuclear membrane, Z-discs and intercalated discs ( Figure 1A ). To isolate the cardiac Pak1, we used bovine ventricle muscle as the source as described in the Methods. About 800 mg of muscle protein extract was obtained from 200 g of the frozen ventricle muscle. Therefore, the yield of muscle extract from the frozen tissue is about 0.4%. Figure 1B illustrates the approach we used for affi nity purifi cation of the Pak1 as described in the Methods. The peptide linked affi nity column was loaded with 5 mg of the protein extracted from the muscle sample. Data in Figure 2A demonstrate that Pak1 is the major component in the eluted fraction as indicated by the resolution of the samples by SDS-PAGE with Coomassie brilliant blue staining ( Figure 3A, lane 3) . Ammonia sulfate fractionation decreased amount of some proteins with the molecular weight larger and smaller than Pak1 ( Figure 3A) . Western blotting analysis ( Figure 2B ) using an antibody (sc-881) identifi ed the bands shown in Figure 2A Pak1 is abundant and has defi ned intracellular localizations in adult rat ventricle myocytes. Localization and expression of Pak1 in rat ventricle myocytes were detected by immuno-fl uorescence and confocal microscopy. Pak1 was stained with fl uorescein Isothiocyanate (FITC) (green). Actin was stained with phalloidin (red). Pak1 is localized to the Z-discs (indicated by the yellow stripes showing overlap of the red and green stains), intercalated discs, nuclear and cell membranes and at the sarcolemmal membrane as emphasized by a bleb in the bottom panel. The myocytes were isolated from rat ventricle as described previously (Ke et al 2004) . B. Schematic representation of purifi cation of Pak1 from cardiac muscle. The purifi cation procedure can be divided into three steps.
Results
Cellular localization and purifi cation of Pak1
Step 1. The decoy peptide derived from Pak1 autoinhibitory region linked to infl uenza hemagglutinin (HA) epitope was bound to HA matrix.
Step 2. Pak1 was bound to the peptide. The matrix was washed with washing buffer.
Step 3 Purifi cation and ceramide activation of Pak1 from heart from the frozen ventricle with a yield of 4%. Therefore, the yield of fi nal affi nity purifi cation product from the frozen ventricle is about 0.016% (w/w). Pak1 bound to the matrix was eluted with 3 mg of HA peptide that displace the decoy peptide from the matrix. The HA peptide in the eluant was separated from Pak1 protein by use of dialysis tubing permeable to proteins smaller than 12-14 kD ( Figure 1B) . The bound Pak1 can also be eluted with Glycine (0.1 M, pH2.0). However, elution with glycine sometimes produces an extra protein bands with molecular weight of 16 kD. Mass spectrometry analysis indicated that the major MS peaks from the digested protein purifi ed matches with Pak1 peptides after trypsin digestion ( Figure 2C ).
In vitro autophosphorylation
Autophosphorylation of Pak1, which correlates with its activity and that we assessed with an in vitro assay, provided a measure of Pak-1 enzyme function. Initial studies (data not shown) indicated that autophosphorylation of the wt Pak1 was much weaker than the constitutively active Pak1 as shown by others (Manser et al 1997) . In all the in vitro assays, we used 4 μg of Pak1 protein. The smaller band (∼48 kD) that could be Pak1 degradation products was also phosphorylated.
The purifi ed Pak1 also demonstrated kinase activity towards the decoy peptide (YNSKKTSNSQKYMSFTDKSA). The decoy peptide contains Pak1 autophosphorylation sites.
The two serine residues that are autophosphorylated are situated at the end of the autoinhibitory sequence. The decoy peptide slightly inhibited autophosphorylation of Pak1. However, it was also phosphorylated and there was a slight increase of the total kinase activity in the presence of the decoy peptide (data not shown).
In view of data reporting a sphingosine-1 induced increase in Pak1 and Pak2 activity in vitro (Bokoch et al 1998; Roig et al 2001) , we also tested the effect of sphingosine and sphingosine-1 phosphate on Pak1 autophosphorylation ( Figure 3A) . Incorporation of 32P from gamma 32P into Pak1 was directly detected by autoradiography after resolving the in vitro reaction products on SDS PAGE. Interestingly, sphingosine-1 phosphate had no signifi cant effect on autophosphorylation of Pak1 at 25 and 50 μM. When the sphingosine phosphate concentration increased to 100 and 200 μM, there was an increase in Pak1 autophosphorylation. In purifi ed Pak1 sample, a 48 kD Pak1 degradation products can sometimes be detected ( Figure 1A , lane 3). When Pak1 activity increased, phosphorylation of the degradation products increased accordingly (Figure 3) . Our results indicated that autophosphorylation of Pak1 purifi ed from cardiac muscle was highly responsive to C 2 and C 6 ceramide ( Figure 4A and B) . Autophosphorylation of the purifi ed Pak1 increased in the presence of 50 and 100 μM of D-sphingosine-1 ( Figure 3B regulated Pak1 autophosphorylation ( Figure 4C ). By gel fi ltration, the purifi ed Pak1 demonstrated a single major peak.
The same experiments were repeated three times each.
Discussion
Our data demonstrating a simple method for purifying native Pak1 from cardiac muscle provide signifi cant new information important in advancing understanding of the Pak-1 signaling in the heart. Moreover, to our knowledge, our data also provide the fi rst evidence demonstrating regulation of the activity of Pak1 by C 2 and C 6 ceramide. Our understanding of Pak1 function in myocardial cells is still in its infancy, and we think the method reported here is an important step in defi ning these functions and their mechanisms. Signaling molecules such as Pak1 are often extensively modifi ed by post-translational mechanisms, and in many cases these modifi cations are associated with pathophysiological conditions. Our method is suitable for study of post-translational modifi cations of Pak1 in response to different extracellular signals and in pathological conditions such as heart failure, arrhythmias, and ischemia. The Pak1 kinase purifi ed by this method can also be used for in vitro kinase assay to identify novel activators or inhibitors. Moreover, the method can be adapted for use in purifi cation of Pak isoforms from mammalian tissues other than heart. The purifi ed Pak1 retained low catalytic activity as demonstrated by autophosphorylation in vitro. The constitutively active Pak1 (T423E) has a much higher level of autophosphorylation than the endogenous Pak1 under the same conditions. We found that autophosphorylation of the purifi ed Pak1 is enhanced by D-sphingosine-1, N-acetyle-sphingosine (C 2 ceramide) and by hexanoyl-sphingosine (C 6 ceramide). This is consistent with an earlier observation that the activities of Pak1 and Pak2 are activated by sphingosine (Bokoch et al 1998; Roig et al 2001) . Our fi nding that active Pak1 induces dephosphorylation of cTnI and C-protein through activation of PP2A (Ke et al 2004) provides a plausible mechanism for induction of protein dephosphorylation by sphingosine. For example, C 2 -ceramide is a known activator of PP2A (Dobrowsky et al 1993) and may be involved in Bcl2 dephosphorylation (Ruvolo et al 1999) . In different types of cells, L-type Ca 2+ channel activity was demonstrated to be depressed by C 2 ceramide by an unknown mechanism (Chik et al 1999 (Chik et al , 2004 . C 2 ceramide also inhibited proliferation of T-cells stimulated by growth signals (O'Byrne and Sansom 2000) . Moreover, C 2 ceramide has preconditioning effects in heart, which has been attributed to generation of reactive oxygen species (Furuya et al 2001; Lecour et al 2006) .
Our data indicate that other mechanisms for C 2 ceramide involving activation of Pak1 and PP2A need to be considered. To our knowledge, this is the fi rst time demonstration that Pak1 is directly stimulated by C 2 and C 6 ceramide. The mechanism whereby Pak1 is activated by sphingosine analogs is still not clear. Our studies indicate that C 2 and C 6 ceramide had stronger effect than sphingosine-1 activating Pak1. Saphingosine only had a small stimulatory effect on Pak1 autophosphorylation. Zenke and colleagues (1999) suggest that sphingosine activates Pak through the P21 binding domain (PBD). However, in another study, Cdc42 and sphingosine-1 appears to have a cooperative effect activating the kinase (Chong et al 2001) . We plan to employ a molecular biology approach to map the amino acid sequence on Pak1 that interacts with sphingosines.
The peptide used to decoy native Pak1 from cardiac muscle is derived from the autoinhibitory region of Pak1 (Manser et al 1997) (Figure 1C ). The autoinhibitory region is both downstream of and partially overlaps with the P 21 binding domain (PBD) (Zhao et al 1998) . A peptide derived from the N-terminal region (the fi rst 21 amino acids of Pak1) that binds to Nck in vitro (Bokoch et al 1998; Zhao et al 2000) also effi ciently retained Pak1 in the column (data not shown). The peptide interacts with the catalytic center of the kinase and may regulate the conformation of the catalytic center as demonstrated by NMR studies (Pirruccello et al 2006) . Expression of the peptide plus the P 21 binding region produced many cellular changes including inhibition of cell cycle progression (Thullberg et al 2007) . The autoinhibitory region was also deleted in GST-Pak1 which was used for in vitro kinase studies (Polverino et al 1995) .
Pak1 is autophosphorylated at multiple serine/threonine sites. There are at least six autophosphorylation sites at the N-terminal half of Pak1 (Manser et al 1997) . Autophosphorylation at the N-terminus of Pak1 may change its intracellular localization or/and activity (Zhao and Manser 2005) . It is unclear at which site autophosphorylation occurs fi rst in the activation of Pak1. Furthermore, uncertainty still remains as to whether autophosphorylation is through interor intramolecular kinase reactions. Since Pak1 dimer has an antiparallel conformation, autophosphorylation sites at the N-terminal half of one Pak1 are therefore placed in proximity to the catalytic domain of the other Pak1 (Lei et al 2000) . This suggests that intermolecular autophosphorylation may occur at the N-terminal autophosphorylation sites.
Pak1 contains a few proline-rich sequences at its N-terminus. The proline-rich sequences interact with proteins, such as Nck and Pix. A prominent feature of these Purifi cation and ceramide activation of Pak1 from heart proline-rich sequences in Pak1 is that they are followed by autophosphorylation sites. Peptide decoy was first designed to identify proteins that interact with the proline rich sequences in the heart. It turned out Pak1 is the only major protein that binds to the decoy peptides, including the peptide containing 22 amino acids (MSNNGLDIQD-KPPAPPMRNTST) at the N-terminal region of the kinase which contains an autophosphorylation site at Serine 21. Substitution of the serine residue for aspartic acid abolished Nck binding to the peptide in vitro (Zhao et al 2000) . In vivo, phosphorylation at the autophosphorylation sites could be a mechanism to release the "autosubstrate" from the catalytic center of the kinase.
Interaction between lipids and a protein kinase may have profound effect on cellular functions (Argraves et al 2002) . The purifi ed Pak1 is stimulated by more than one sphingosine species. It is likely that some other sphingosine related lipids may also regulate Pak1 activity. Modifi cation of the side chain and the polar groups of sphingosines may produces agonists or antagonists that have even more potent effect on Pak1 autophosphorylation.
